Dai, Ming-Shen
Tri-Service General Hospital · Chi Mei Medical Center
3 papers on CoChatORCID 0000-0002-3953-5243
Most cited papers
- Verified
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 604
- Verified
Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: findings from the multinational, randomized, phase III NALA trial
Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W. J., Masuda, N., et al. (2019) · Journal of Clinical Oncology
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 99
- Verified
Radiofrequency Ablation of Hepatic Metastases: Factors Influencing Local Tumor Progression
Liu, C.-H., Yu, C.-Y., Chang, W.-C., Dai, M.-S., Hsiao, C.-W., & Chou, Y.-C. (2014) · Annals of Surgical Oncology
Hepatocellular Carcinoma Treatment and PrognosisIntraperitoneal and Appendiceal Malignancies
Cited by 10
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free